Entrectinib is produced by which company?

Entrectinib (Entrectinib) is sold in China under the trade name "Luo Shengquan". It is an innovative targeted drug developed and produced by the Swiss pharmaceutical giant Roche. Its research and development originated from the cooperation between Genentech, a pharmaceutical subsidiary of Roche, and Ignyta. It was initially developed by Ignyta, and was later acquired by Roche and completed subsequent clinical and commercialization layout. As a leading international precision medicine drug, the emergence of entrectinib marks a new stage in the treatment of tumors related to NTRK and ROS1 gene fusion.

Compared with traditional cancer treatment methods, entrectinib's research and development ideas are more in line with the "target-driven" modern oncology concept. Roche has always been at the forefront of global drug innovation, especially in the research and development pipeline of anti-tumor drugs, where targeted therapy and immunotherapy occupy an important position. The launch of entrectinib not only enriches the treatment options for lung cancer, sarcoma and other NTRK fusion tumors, but also promotes the popularization of genetic testing and personalized treatment in clinical practice to a certain extent.

It is worth noting that Roche has verified the effectiveness and safety of entrectinib through global multi-center clinical studies, and has simultaneously promoted registration approval in multiple countries and regions. In 2019, the US FDA took the lead in approving this drug for the treatment of patients with NTRK gene fusion-positive solid tumors. This is another breakthrough "pan-tumor" targeted drug after larotrectinib. Subsequently, entrectinib was also approved by the European Union and Japanese drug regulatory agencies, making it one of the most influential precision treatment options internationally.

In China, entrectinib has been introduced and successfully launched by Roche, and will soon be included in the medical insurance catalog. This progress will undoubtedly reduce the economic burden and improve the accessibility of drugs for patients who require long-term targeted treatment of non-small cell lung cancer.

Reference materials:https://www.roche.com/products/rozlytrek